Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Background: Teneligliptin is a 3rd-generation dipeptidyl peptidase-4 (DPP-4) inhibitor. There is a limited evidence regarding the effect of teneligliptin. Therefore, this study is to assess the efficacy and safety of teneligliptin in type 2 diabetes mellitus (T2DM) patients with inadequately glycemi...

Full description

Bibliographic Details
Main Authors:	Xiaoxuan Li, Xuefei Huang, Chongfei Bai, Dalian Qin, Shousong Cao, Qibing Mei, Yun Ye, Jianming Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-05-01
Series:	Frontiers in Pharmacology
Subjects:	teneligliptin dipeptidyl peptidase-4 (DPP-4) inhibitor type 2 diabetes mellitus (T2DM) systematic review glycemic control
Online Access:	http://journal.frontiersin.org/article/10.3389/fphar.2018.00449/full

Similar Items

Teneligliptin in management of type 2 diabetes mellitus
by: Sharma SK, et al.
Published: (2016-08-01)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
by: Ghosh S, et al.
Published: (2016-11-01)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
by: Han E, et al.
Published: (2020-11-01)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020-04-01)

Mild cognitive decline in type 2 diabetes mellitus patients – risk factors and pathogenesis: role of DPP4 activity and future possible therapeutic targets
by: Gul O, et al.
Published: (2019-02-01)

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
by: Munehiro Kitada, et al.
Published: (2019-05-01)

Renoprotective effects of teneligliptin: An observational study
by: Prabhat Agrawal, et al.
Published: (2021-01-01)

Teneligliptin-induced hair loss: A case report
by: Prabhat K Agrawal, et al.
Published: (2020-01-01)

Saxagliptin for type 2 diabetes
by: Chacra
Published: (2010-09-01)

Efficacy and safety of teneligliptin in Indian patients with inadequately controlled Type 2 diabetes mellitus: A randomized, double-blind study
by: Piyush Agarwal, et al.
Published: (2018-01-01)

Teneligliptin Exerts Antinociceptive Effects in Rat Model of Partial Sciatic Nerve Transection Induced Neuropathic Pain
by: Yaswanth Kuthati, et al.
Published: (2021-09-01)

Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01)

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
by: Karyekar CS, et al.
Published: (2013-04-01)

Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes
by: Hsin-Hung Chen, et al.
Published: (2019-04-01)

Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
by: Linong Ji, et al.
Published: (2021-04-01)

DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
by: Erna Kristin
Published: (2016-12-01)

Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs
by: Chiranjib Chakraborty, et al.
Published: (2017-01-01)

The regulatory role of DPP4 in atherosclerotic disease
by: Lihua Duan, et al.
Published: (2017-06-01)

Teneligliptin in Early Diabetic Kidney Disease: An Observation in Asian Indian Patients with Type 2 Diabetes Mellitus in Real-Life Scenario
by: Kiran Shah
Published: (2017-06-01)

Teneligliptin in Management of Diabetic Kidney Disease: A Review of Place in Therapy
by: Mohammed Abubaker, et al.
Published: (2017-01-01)

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid
by: Ágnes Kinyó, et al.
Published: (2021-04-01)

Oxytocin May be Superior to Gliptins as a Potential Treatment for Diabetic COVID-19 Patients
by: Phuoc-Tan Diep
Published: (2021-01-01)

Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital
by: Woh Yon Mak, et al.
Published: (2020-06-01)

Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer
by: Chintan Shah, et al.
Published: (2020-03-01)

Corrigendum: A Multi-Mode Bioactive Agent Isolated From Ficus microcarpa L. Fill. With Therapeutic Potential for Type 2 Diabetes Mellitus
by: Nosheen Akhtar, et al.
Published: (2019-06-01)

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
by: Takayasu Ideta, et al.
Published: (2015-12-01)

Systematic review of clinical and economic effectiveness of vildagliptin in type 2 diabetic patients with poor glycemic control on monotherapy with metformin
by: Alima Almadiyeva, et al.
Published: (2018-12-01)

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
by: Jin-Sun Chang, et al.
Published: (2013-02-01)

The rs12617336 and rs17574 Dipeptidyl Peptidase-4 Polymorphisms Are Associated With Hypoalphalipoproteinemia and Dipeptidyl Peptidase-4 Serum Levels: A Case-Control Study of the Genetics of Atherosclerotic Disease (GEA) Cohort
by: Gilberto Vargas-Alarcón, et al.
Published: (2021-06-01)

Gemigliptin: Newer promising gliptin for type 2 diabetes mellitus
by: Manish Gutch, et al.
Published: (2017-01-01)

Repurposing of FDA-Approved NSAIDs for DPP-4 Inhibition as an Alternative for Diabetes Mellitus Treatment: Computational and in Vitro Study
by: Veera C. S. R. Chittepu, et al.
Published: (2019-05-01)

A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus
by: Tanya Tandon, et al.
Published: (2019-01-01)

Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis
by: Okuda Y, et al.
Published: (2016-04-01)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
by: Jin-Woo Park, et al.
Published: (2021-08-01)

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study
by: Linong Ji, et al.
Published: (2021-04-01)

An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin
by: Yoshia Miyawaki, et al.
Published: (2018-10-01)

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus
by: Choi YJ, et al.
Published: (2019-08-01)

The effect of sitagliptin on hepatic ischemic reperfusion injury in rats
by: Song-Chol Mun, et al.
Published: (2020-01-01)

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
by: Naoko Tajima, et al.
Published: (2020-05-01)

QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study)
by: Erande S, et al.
Published: (2019-06-01)